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ABSTRAK
 Latar belakang: hubungan antara diabetes melitus (DM) dan Multi Drug Resistant Tuberculosis (MDR-TB) belum 
pernah diteliti di antara pasien Tuberkulosis (TB) di Indonesia, sedangkan DM diketahui dapat mengganggu respons 
kekebalan tubuh dan memengaruhi farmakokinetik obat TB sehingga dapat menyebabkan kegagalan pengobatan TB 
dan terjadinya MDR-TB. Penelitian ini bertujuan untuk menganalisis pengaruh DM pada perkembangan MDR-TB. 
Metode: studi kohort retrospektif dilakukan dengan melibatkan 356 pasien TB di Balai Pengobatan Paru-paru 
(BP4) dan Rumah Sakit Sardjito, Yogyakarta, Indonesia pada tahun 2010-2014. Diagnosis MDR-TB ditentukan 
dengan GeneXpert atau drug sensitivity testing, sementara DM ditentukan berdasarkan kriteria pedoman 
nasional. Beberapa variabel demografik, epidemiologi, dan hasil pengobatan dikumpulkan. Rasio odds (OR) dan 
selang kepercayaan 95% (95% CI) dianalisis dengan simple logistic regression. Hasil: di antara 356 pasien TB, 
23 orang adalah pasien dengan DM, sedangkan 333 pasien tidak menderita DM. Pasien dengan tuberkulosis 
dan diabetes melitus memiliki risiko 6,8 lebih besar (95% CI:2,0-23,7, p=0,003) untuk berkembang menjadi 
MDR-TB. Individu dengan tuberkulosis dan diabetes melitus memiliki kemungkinan 4,4 lebih besar (95% 
CI:1,5-12,9, p=0,008) untuk memiliki hasil sputum positif pada bulan kedua pengobatan yang mengindikasikan 
keterlambatan dalam proses penyembuhan dari tuberkulosis. Kesimpulan: terdapat hubungan yang bermakna 
antara diabetes melitus dengan perkembangan MDR-TB. Oleh karenanya, direkomendasikan bagi klinisi di semua 
lapis pelayanan kesehatan untuk melakukan tes skrining MDR-TB di antara pasien kelompok ini. Penelitian 
kohort prospektif perlu dilakukan untuk mengkonfirmasi hasil dari penelitian pendahuluan ini.
Kata kunci: diabetes melitus, tuberkulosis, faktor risiko, Indonesia.
ABSTRACT
Aim: the correlation between diabetes mellitus (DM) and Multi-Drug-Resistant Tuberculosis (MDR-TB) 
has never been studied among patients with tuberculosis (TB) in Indonesia, while DM has been identified to 
alter immune response and pharmacokinetics of TB medications that may lead to a failure of TB treatment 
and develop MDR-TB. Our study aimed to analyze the influence of diabetes mellitus on the development of 
MDR-TB. Methods: a retrospective cohort study was carried out on 356 TB patients at the Provincial Lung 
Clinics and Sardjito Hospital, Yogyakarta, Indonesia between 2010 and 2014. Diagnosis of MDR-TB was 
established based on GeneXpert or drug sensitivity testing, while DM was determined based on the criteria in 
the National Guidelines. Demographic, epidemiological and outcome variables were collected. Odds ratios 
and 95% confidence intervals (95% CI) were analyzed using simple logistic regression. Results: among 356 
TB patients, 23 patients were with binomial TB-DM, while 333 patients did not suffered from DM. Patients 
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with TB-DM presented a 6.8-fold (95% CI:2.0-23.7, p=0.003) higher risk of developing MDR-TB. Individuals 
with TB-DM had a 4.4-fold (95% CI:1.5-12.9, p=0.008) greater chance to have positive sputum smear by the 
second month of treatment indicating a delay in the resolution of the tuberculosis infection. Conclusion: there 
was a significant correlation between diabetes mellitus and MDR-TB development. Therefore, it is suggested 
that clinicians at all levels of health care service should conduct any kind of screening test for MDR-TB in such 
group of patients. Further prospective cohort study is needed to confirm the findings of this preliminary study.
Keywords: diabetes mellitus, tuberculosis, risk factors, Indonesia.
INTRODUCTION
Diabetes mellitus (DM) influences the 
natural development of tuberculosis (TB) 
through depressed cellular immunity, alveolar 
macrophages dysfunction, low interferon 
gamma level, pulmonary microangiopathy and 
micronutrient deficiency.1,2 Globally, 70% of 
diabetics live in TB endemic countries. Type-2 
DM was found in around 2 - 9% of the population 
in 22 countries with the highest burden of TB.3 
Indonesia, with the second highest burden of TB 
in the world,4 has the seventh largest number of 
diabetics.5 The prevalence of Type-2 DM among 
TB patients in Indonesia was relatively low 
(13.2%). However, it was significantly associated 
with TB.6
Indonesia is also one of the ten countries that 
currently have been estimated to have the highest 
number of Multi Drug Resistant-Tuberculosis 
(MDR-TB).4 MDR-TB is TB that does not 
respond to at least isoniazid and rifampicin 
treatment, the main anti-TB medications.4 The 
prevalence of type-2 DM among MDR-TB 
patients in Indonesia has not yet been known. 
However, some studies have revealed that 
type-2 DM has been found among 18.8-23.3% 
of MDR-TB patients in some public hospitals 
in Indonesia.7,8 The association between type-
2 DM and MDR-TB is not entirely clear and 
different studies have revealed conflicting results. 
Some studies demonstrated that there was no 
association between type-2 DM and MDR-TB,9,10 
while other reported that the risk of MDR TB 
increased among diabetic patients.11,12 However, 
type-2 DM has been shown to increase the risk 
of delayed sputum conversion and treatment 
failure.6,11,13
The correlation between type-2 DM and 
MRD -TB has never been studied among patients 
with TB in Indonesia. Therefore, our study aimed 
to analyze the influence of type-2 DM on the 
development of MDR-TB in Indonesia.
METHODS
As a preliminary study, our retrospective 
cohort study was carried out involving all TB 
patients who were admitted to the Provincial 
Lung Clinics and Dr. Sardjito Referral Hospital, 
Yogyakarta, Indonesia between 2010 and 2014. 
The criteria for establishing the diagnosis of type-
2 DM was in line with the National Guidelines 
and was carried out by a physician. Individuals 
who had fasted for at least 8 hours and showed a 
plasma glucose concentration of ≥126 mg/dl were 
considered diabetic.14 The diagnosis of DM was 
also made if patients had a history of known DM 
or had received antidiabetic agents. Diagnosis  of 
TB was established based on clinical examination, 
positive sputum smear examination for acid-
fast bacilli (AFB) and or positive chest X-ray, 
which were consistent with the National and 
International Guidelines.15 All TB patients were 
treated according to the National and International 
Guidelines.15 MDR-TB diagnosis was determined 
by an examination using GeneXpert MTB/RIF 
(Cepheid, US) or drug sensitivity testing at the 
Laboratory of TB, Department of Microbiology, 
Faculty of Medicine, Universitas Gadjah Mada, 
Yogyakarta. At the beginning of treatment, a 
routine blood examination was conducted, and 
Human Immunodeficiency Virus (HIV) testing 
was performed for all patients.
Patient Selection
All pulmonary TB patients who were 
treated at the Provincial Lung Clinics and Dr. 
Sardjito Hospital were included in our study. 
MDR-TB patients were selected based on the 
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results of drug sensitivity or GeneXpert testing, 
which were registered in their medical records. 
Exclusion criteria were those who were less 
than 18 years old and had incomplete medical 
record. The study was conducted in accordance 
to the Helsinki Declaration of 2008 and had been 
approved by the Medical and Health Research 
Ethics Committee at Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta, Indonesia 
on November 3rd, 2012 with reference number 
KE/FK/855/EC. Based on the calculation of 
sample size formula for a cohort study (Zα=1.96, 
p0=2.8%, p1=23.3%, Zβ=0.80, and m=6.58; 
based on previous data on DM prevalence of 
TB and MDR-TB patients in Indonesia), the 
minimum sample needed in the exposed group 
was 24 patients. Since it was a preliminary 
study, 23 patients were considered as acceptable 
sample size.
Data Collection
Epidemiological and clinical variables were 
obtained from medical records. The collected 
data variables were age, sex, body mass index 
(BMI), smoking status, an ethnic group, history 
of TB contact, history of TB treatment, result 
of sputum smear taken at the time of diagnosis 
and after two months of treatment, presence of a 
cavitary lesion on chest X-ray, and results of drug 
resistance test. Study participants were followed-
up retrospectively through medical record until 
the end of treatment.
Data Analysis
Bivariate analysis was carried out using 
Chi square test or Fisher’s exact test. A logistic 
regression was carried out to determine whether 
the type-2 DM was associated with multi drug 
resistance tuberculosis. Univariate test were done 
to type-2 DM and other factors. Factors with 
p<0.20 then were included in the multivariate 
model, p<0.05 was considered significant. 
Odds ratios (OR) and 95% confidence intervals 
(95% CI) were also calculated. SPSS software 
program version 24.0 (IBM, USA) was used for 
the calculations.
RESULTS
We excluded 35 patients due to incomplete 
data. Table 1 shows general characteristics of 
356 individuals included in the study. Among the 
356 TB patients, 23 patients were with binomial 
tuberculosis – diabetes mellitus and 333 TB 
patients did not suffered from diabetes mellitus. 
Demographic characteristics were similar between 
TB patients with and without DM. Patient with 
DM had more cavitary lesion (p=0.005) and 
positive sputum smear examination after two 
months treatment (p=0.2) than those without DM.


















Age >37 years 12 (52.17) 131 (39.30)
143 
(40.20)
Male sex 17 (73.91) 205 (61.56)
222 
(62.36)







 - Javanese 21 (91.30) 304 (91.29)
325 
(91.29)
 - Others 
(Sundanese, 
Batak, others)
2 (8.70) 29 (8.71) 31 (8.71)
History of smoking 7 (30.4) 113 (33.9) 120 (33.7)
History of TB 
contact 5 (21.7) 93 (27.9) 98 (27.53)
Previous TB 
treatment 3 (13.0) 17 (5.1) 20 (5.6)









result at 2 mo of 
treatment
5 (21.7) 20 (6.01) 25 (7.0)
MDR-TB 4 (17.4) 10 (3.0) 14 (3.93)
SD: standard deviation; SSM: sputum smear 
examination; a Data are n (%) unless otherwise stated
Table 2 shows factors significantly associated 
with MDR-TB development, which include 
age older than 37 years old (p=0.04), female 
(p=0.04), had previous TB treatment (p<0.001) 
and was with DM (p=0.009). Among the TB-DM 
patients, 4 patients (17.4%) developed MDR-TB. 
The univariate analysis showed that patients 
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with binomial tuberculosis - diabetes mellitus 
presented a 6.8-fold (95% CI:2.0-23.7, p=0.003) 
higher risk of developing MDR-TB compared 
to those without DM (Table 3). Meanwhile, the 
effect of DM increased (OR=17.9, 95%CI: 3.3-
96.8) when analyzed together with other factors. 
Factor of previous TB treatment was not included 
in the multivariate analysis because of its wide 
confidence interval. Individuals with binomial 
tuberculosis- diabetes mellitus had a 4.4-fold 
(95% CI:1.5-12.9, p=0.008) greater chance to 
have positive tuberculosis result of sputum smear 
after the second month of treatment indicating 
a delay in the resolution of the tuberculosis 
infection (Table 4).
Table 2. Factors associated with MDR-TBa
Characteristics
MDTR-TB
Total (N=356) P valueb
Yes No
Age >37 years 11 (78.6) 132 (38.6) 143 (40.2) 0.004
Female sex 9 (64.3) 125 (36.5) 134 (37.6) 0.04
BMI <18.5 or >25 kg/m2 14 (100) 265 (77.5) 279 (78.37) 0.05
Ethnic group:
 - Javanese 14 (100) 311 (90.9) 325 (91.29) 0.62
 - Others (Sundanese, Batak, others) 0 (0.0) 31 (9.1) 31 (8.71)
History of smoking 2 (14.3) 118 (34.5) 120 (33.7) 0.15
History of TB contact 2 (14.3) 96 (28.1) 98 (27.53) 0.37
Previous TB treatment 13 (92.9) 7 (2.0) 20 (5.6) <0.001
Cavitary lung lesion on radiology 1 (7.1) 95 (27.8) 96 (26.97) 0.12
Positive SSM result at diagnosis 12 (85.7) 326 (95.3) 338 (94.94) 0.15
Positive SSM result after 2 mo of treatment 2 (14.3) 23 (6.7) 25 (7.0) 0.26
Presence of DM 4 (28.6) 19 (5.6) 23 (6.5) 0.009
a Data are n (%) unless otherwise stated.
b Chi square test or Fisher’s exact test were used when appropriate







OR (95% CI) P-valuea OR (95% CI) P-valueb
Age>37 years 160 (44.94) 10 (71.43) 5.8 (1.6-21.3) 0.01 6.7 (1.7-26.3) 0.01
Female sex 134 (37.6) 9 (64.3) 3.12 (1.0-9.5) 0.045 6.1 (1.4-26.8) 0.02
History of smoking 120 (33.7) 2 (14.3) 0.3 (0.1-1.4) 0.14 0.3 (0.1-1.7) 0.20
Previous TB treatment 20 (5.6) 13 (92.9) 622.1 (71.2-5434.2) <0.001 - -
Cavitary lung lesion on 
radiology 96 (27.0) 1 (7.1) 0.2 (0.03-1.6) 0.12 0.1 (0.01-1.1) 0.06
Positive SSM result at 
diagnosis 338 (94.9) 12 (85.7) 0.3 (0.1-1.4) 0.13 0.4 (0.1-2.2) 0.30
DM 23 (6.5) 4 (28.6) 6.8 (2.0 – 23.7) 0.003 17.9 (3.3-96.8) 0.001
a Calculated with simple logistic regression; b Calculated with multiple logistic regression.
Table 4. Association between DM and positive SSM result after 2 months of treatment
Variables Total - n (%) TB-DM - n (%) TB-non DM - n (%) OR (95% CI) P value
Positive SSM result at 2 mo of 
treatment 25 (7) 5 (21.7) 20 (6) 4.4 (1.5-12.9) 0.008
a Calculated with simple logistic regression
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DISCUSSION
Our study showed that type 2 DM was 
significantly associated with the development 
of MDR-TB in Yogyakarta, Indonesia. The 
mechanism could be explained by lower plasma 
concentrations of anti TB drugs, particularly 
rifampicin,16 due to altered drug absorption, 
distribution, metabolism and excretion in TB 
patients with DM. The intestinal motility in 
diabetics is also lower, thus reduces gastric 
emptying, changes the pH levels and results in 
delayed absorption of some drugs. Moreover, 
a study showed that TB diabetic patients had 
rifampicin serum levels that were 53% lower in 
TB non-diabetic patients.16 The low plasma level 
of anti-TB drugs was proposed to cause poor 
treatment outcome, in which risk on treatment 
failure was almost nine folds higher in patients 
with low drug exposure compared to patients with 
higher drug exposure. Furthermore, it also has 
an association with acquired drug resistance.17,18 
Another hypothesis includes the mutations of 
katG gene. The gene has a function to protect the 
Mycobacterium tuberculosis against oxidative 
stress and to encode catalase-peroxidase that 
induces isoniazid into its active form. In diabetic 
patients, there might be improved production of 
reactive oxygen species, thus the strains with 
such mutations are more likely to survive.19,20
Our study also revealed that diabetic TB 
patients had delayed resolution of  tuberculosis 
infection as shown by positive tuberculosis 
result of sputum smears in the second month 
of treatment. The findings are consistent with 
results of previous study that has identified a 
longer sputum conversion time in diabetic TB 
patients compared to non-diabetics.21 It might 
be related to altered immune response against 
tuberculosis found in diabetic patients, thus 
leading to higher baseline mycobacterial burdens 
in comparison to non-diabetic patients and 
resulting in longer sputum conversion time.21,22 
Moreover, another study in Indonesia revealed 
that despite the similarity of culture conversion 
proportions for diabetic TB patients and non-
diabetic TB patients after 2 months of treatment, 
the rate of treatment failure among diabetic TB 
patients was higher (22.2%) compared to the 
rate among non-diabetic TB patients (9.6%).23 
Meanwhile, patients with previous treatment 
failure will obtain longer treatment duration, 
which will increase the likelihood of developing 
drug-resistant mutation.
We also found that patients with DM in our 
study had more cavitary lesions. Our finding 
is in accordance with results of some previous 
studies,22,24 and the reason proposed was due 
to uncontrolled glycemic level (HbA1c≥7) or 
insulin dependency.9 However, we could not 
collect data of neither HbA1c levels nor insulin 
dependency. Therefore, we could not confirm the 
hypothesis. In addition to the presence of diabetes 
mellitus, our data also revealed that being older 
than 37 years old, female and had previous TB 
treatment gave higher risk of developing MDR-
TB. Previous studies indicated conflicting results 
for older age as a predisposing factor for MDR-
TB.25,26 However, in our study, it might be caused 
by the delayed diagnosis of MDR-TB since 
the free-cost and prompt diagnosis device for 
MDR-TB (GeneXpert) in Yogyakarta was just 
available recently in 2012. Female gender as a 
risk factor for the development of MDR-TB may 
be explained by low health-care seeking behavior 
among women when the disease was still not 
progressive, which corresponds with results 
of an earlier study.27 However, the role of this 
factor needs further investigation. Meanwhile, 
a history of previous TB treatment has already 
been stated as one of the strongest predisposing 
factors of MDR-TB by WHO and some previous 
studies. It may be caused by multi-factorial 
causes, such as non-adherence, low level of 
drugs, poor health system, and human error.4,10,28 
In 2015, WHO reported that 12% of TB patients 
in Indonesia who were treated for TB in the past 
were estimated to develop MDR-TB.4
To prevent the development of MDR-TB 
among TB diabetic patients, clinicians need to 
pay attention on the co-management of TB and 
DM. A glycemic control could be hindered by 
TB infection, especially in the early stage of TB 
treatment. In this stage, increased inflammation 
would occur due to early bacterial killing, which 
may escalate insulin resistance.29 Furthermore, 
there is a drug-drug interaction between TB and 
DM drugs. Rifampicin decreases the plasma 
levels of some oral anti-diabetic drugs, especially 
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sulphonylureas and biguanides; while in patients 
using isoniazid, worse glycemic control may occur 
due to sulphonylureas.30 Moreover, rifampicin 
serum levels in TB diabetic patients are lower 
than TB non-diabetic patients.16 In addition, 
the side effects of co-administrating TB and 
diabetes medications might influence patient 
adherence, which is another predisposing factor 
for developing MDR-TB. Therefore, a strict 
glycemic control together with  monitoring the 
blood levels of anti-diabetes and anti-TB drugs 
during TB treatment may give benefits to improve 
treatment outcome. Despite having high numbers 
of estimated cases of DM and MDR-TB,4,5 the 
integrated systems for communicable and non-
communicable diseases have not yet been well 
developed in Indonesia.
There are some limitations in our study. 
The results of sputum examination is limited 
to the results of sputum smear on microscopic 
examination since culture examination is 
expensive and rarely conducted although culture 
would provide more information. Our study 
also has a relatively small sample size, thus our 
findings need to be confirmed in larger sample 
and in this way, we may assess other risk factors 
for drug resistance.
CONCLUSION
Our study shows that diabetes mellitus 
increases the risk of developing MDR-TB. 
Therefore, it is suggested that clinicians at all 
levels of health care service should make an 
appropriately targeted early clinical suspicion 
and conduct any kind of screening test of 
MDR-TB for such group of patients. Further 
prospective cohort study should be conducted 
to confirm these preliminary findings.
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